225 related articles for article (PubMed ID: 21083926)
1. Occult hepatitis B infection in egyptian chronic hepatitis C patients: prevalence, impact on pegylated interferon/ribavirin therapy.
Emara MH; El-Gammal NE; Mohamed LA; Bahgat MM
Virol J; 2010 Nov; 7():324. PubMed ID: 21083926
[TBL] [Abstract][Full Text] [Related]
2. Prevalence and impact of occult hepatitis B infection in chronic hepatitis C patients treated with pegylated interferon and ribavirin.
Levast M; Larrat S; Thelu MA; Nicod S; Plages A; Cheveau A; Zarski JP; Seigneurin JM; Morand P; Leroy V
J Med Virol; 2010 May; 82(5):747-54. PubMed ID: 20336715
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic effects of pegylated interferon plus ribavirin in chronic hepatitis C patients with occult hepatitis B virus dual infection.
Chen LW; Chien RN; Yen CL; Chang JJ; Liu CJ; Lin CL
J Gastroenterol Hepatol; 2010 Feb; 25(2):259-63. PubMed ID: 19817959
[TBL] [Abstract][Full Text] [Related]
4. Occult HBV infection and suppression of HCV replication in the early phase of combination therapy for chronic hepatitis C.
Ferraro D; Bonura C; Giglio M; Di Stefano R; Almasio PL; Di Marco V; Craxì A; Cacciola I; Squadrito G; Raimondo G
J Biol Regul Homeost Agents; 2003; 17(2):172-5. PubMed ID: 14518718
[TBL] [Abstract][Full Text] [Related]
5. Chronic hepatitis C responds poorly to combination therapy in chronic hepatis B carriers.
Senturk H; Tahan V; Canbakan B; Uraz S; Ulger Y; Ozaras R; Tabak F; Mert A; Ozbay G
Neth J Med; 2008 May; 66(5):191-5. PubMed ID: 18490796
[TBL] [Abstract][Full Text] [Related]
6. Analysis of HCV co-infection with occult hepatitis B virus in patients undergoing IFN therapy.
Khattab E; Chemin I; Vuillermoz I; Vieux C; Mrani S; Guillaud O; Trepo C; Zoulim F
J Clin Virol; 2005 Jun; 33(2):150-7. PubMed ID: 15911431
[TBL] [Abstract][Full Text] [Related]
7. Sustained HCV-RNA response and hepatitis Bs seroconversion after individualized antiviral therapy with pegylated interferon alpha plus ribavirin and active vaccination in a hepatitis C virus/hepatitis B virus-coinfected patient.
Potthoff A; Deterding K; Trautwein C; Rifai K; Manns MP; Wedemeyer H
Eur J Gastroenterol Hepatol; 2007 Oct; 19(10):906-9. PubMed ID: 17873617
[TBL] [Abstract][Full Text] [Related]
8. Co-infection with hepatitis B does not alter treatment response in chronic hepatitis C.
Uyanikoglu A; Akyuz F; Baran B; Simsek BP; Ermis F; Demir K; Gulluoglu M; Badur S; Kaymakoglu S
Clin Res Hepatol Gastroenterol; 2013 Nov; 37(5):485-90. PubMed ID: 23665172
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of double filtration plasmapheresis with pegylated interferon/ribavirin therapy for intractable chronic hepatitis C patients and hepatitis C patients with combined liver cirrhosis by HBV, leading to early viral elimination.
Ohara T; Oteki T; Suzuki T; Suzuki M; Matsuzaki Y
Hepatogastroenterology; 2011; 58(105):133-6. PubMed ID: 21510300
[TBL] [Abstract][Full Text] [Related]
10. Occult hepatitis B virus infection does not affect liver histology or response to therapy with interferon alpha and ribavirin in intravenous drug users with chronic hepatitis C.
Fabris P; Brown D; Tositti G; Bozzola L; Giordani MT; Bevilacqua P; de Lalla F; Webster GJ; Dusheiko G
J Clin Virol; 2004 Mar; 29(3):160-6. PubMed ID: 14962784
[TBL] [Abstract][Full Text] [Related]
11. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses.
Liu CJ; Chuang WL; Lee CM; Yu ML; Lu SN; Wu SS; Liao LY; Chen CL; Kuo HT; Chao YC; Tung SY; Yang SS; Kao JH; Liu CH; Su WW; Lin CL; Jeng YM; Chen PJ; Chen DS
Gastroenterology; 2009 Feb; 136(2):496-504.e3. PubMed ID: 19084016
[TBL] [Abstract][Full Text] [Related]
12. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease.
Cacciola I; Pollicino T; Squadrito G; Cerenzia G; Orlando ME; Raimondo G
N Engl J Med; 1999 Jul; 341(1):22-6. PubMed ID: 10387938
[TBL] [Abstract][Full Text] [Related]
13. Sustained HCV clearance by interferon-based therapy reduces hepatocellular carcinoma in hepatitis B and C dually-infected patients.
Hung CH; Lu SN; Wang JH; Hu TH; Chen CH; Huang CM; Lee CM
Antivir Ther; 2011; 16(7):959-68. PubMed ID: 22024511
[TBL] [Abstract][Full Text] [Related]
14. Virological profiles in hepatitis B virus/hepatitis C virus coinfected patients under interferon plus ribavirin therapy.
Saitta C; Pontisso P; Brunetto MR; Fargion S; Gaeta GB; Niro GA; Picciotto A; Smedile A; Squadrito G; Raimondo G
Antivir Ther; 2006; 11(7):931-4. PubMed ID: 17302256
[TBL] [Abstract][Full Text] [Related]
15. Occult HBV infection may represent a major risk factor of non-response to antiviral therapy of chronic hepatitis C.
Mrani S; Chemin I; Menouar K; Guillaud O; Pradat P; Borghi G; Trabaud MA; Chevallier P; Chevallier M; Zoulim F; Trépo C
J Med Virol; 2007 Aug; 79(8):1075-81. PubMed ID: 17596829
[TBL] [Abstract][Full Text] [Related]
16. The influence of occult infection with hepatitis B virus on liver histology and response to interferon treatment in chronic hepatitis C patients.
Silva Cd; Gonçales NS; Pereira JS; Escanhoela CA; Pavan MH; Gonçales FL
Braz J Infect Dis; 2004 Dec; 8(6):431-9. PubMed ID: 15880234
[TBL] [Abstract][Full Text] [Related]
17. Antibody to hepatitis B core antigen as a screening test for occult hepatitis B virus infection in Egyptian chronic hepatitis C patients.
El-Sherif A; Abou-Shady M; Abou-Zeid H; Elwassief A; Elbahrawy A; Ueda Y; Chiba T; Hosney AM
J Gastroenterol; 2009; 44(4):359-64. PubMed ID: 19271112
[TBL] [Abstract][Full Text] [Related]
18. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
[TBL] [Abstract][Full Text] [Related]
19. Virological pattern in plasma, peripheral blood mononuclear cells and liver tissue and clinical outcome in chronic hepatitis B and C virus coinfection.
Coppola N; Pisapia R; Tonziello G; Martini S; Imparato M; Piai G; Stanzione M; Sagnelli C; Filippini P; Piccinino F; Sagnelli E
Antivir Ther; 2008; 13(2):307-18. PubMed ID: 18505182
[TBL] [Abstract][Full Text] [Related]
20. Hydroxychloroquine augments early virological response to pegylated interferon plus ribavirin in genotype-4 chronic hepatitis C patients.
Helal GK; Gad MA; Abd-Ellah MF; Eid MS
J Med Virol; 2016 Dec; 88(12):2170-2178. PubMed ID: 27183377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
